Investors who Lost Money on Intellia Therapeutics, Inc. (NTLA) Should Contact Levi & Korsinsky About Pending Class Action - NTLA
Portfolio Pulse from
Levi & Korsinsky law firm has filed a class action securities lawsuit against Intellia Therapeutics (NTLA) alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study and failed to disclose the declining relevance of viral-based editing. On January 9, 2025, Intellia announced a major reorganization, halting NTLA-3001 research and reducing workforce by 27%, causing the stock price to drop from $12.02 to $10.20.
April 10, 2025 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics faces potential legal and financial challenges following the discontinuation of NTLA-3001 research and a class action lawsuit alleging securities fraud.
The lawsuit and research program discontinuation suggest significant operational challenges and potential financial penalties, which could negatively impact NTLA's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100